Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
Senti Biosciences Inc (NASDAQ:SNTI) shares are trading higher by 102.6% to $0.56 during Monday's session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202.
Senti Biosciences股票（納斯達克：SNTI）在週一交易中上漲102.6%，至0.56美元，此前該公司獲得了來自加利福尼亞再生醫學研究所的800萬美元資助，以支持SENTI-202的持續發展。
The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.
該公司表示，SENTI-202是一種用於治療復發/難治的血液惡性腫瘤，包括急性髓性白血病（AML）的研究性細胞療法。進行中的第一階段試驗旨在在2024年底之前提供初步療效數據，並在2025年提供持久性數據。
Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM's support, highlighting SENTI-202's potential to improve AML treatment. The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.
Senti Bio的首席執行官兼聯合創始人Timothy Lu感謝CIRM的支持，並強調SENTI-202有望改善AML治療。該試驗在美國和澳大利亞招募特定血液惡性腫瘤的成人患者，評估經過疾病特異性預處理的兩個劑量級別的SENTI-202細胞在週期內的輸注情況。
Read Also: What's Going On With GameStop Stock Monday?
閱讀更多：GameStop股票週一發生了什麼？
Is SNTI A Good Stock To Buy?
SNTI股票是否值得買入？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Senti Biosciences's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投資者在決定一個股票是否值得買入時可以做出一些決策。除了估值指標和價格行爲（可以在Benzinga的報價頁面上找到，例如Senti Biosciences的頁面），還有一些因素，例如公司是否支付股息或每個季度購買大量股票。這些被稱爲資本配置計劃。Senti Biosciences（納斯達克：SNTI）不支付股息，但顯然有幾種方法可以爲股東回報價值。你可以自由地在Benzinga的股息日曆中搜索下一個計劃支付股息的公司，並確定你持有該公司的股份可以獲得多少收益率。
These are known as capital allocation programs. Senti Biosciences (NASDAQ:SNTI) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
股票回購計劃顯然是不同的，並且高度可變。公司可以批准股票回購計劃，並根據授權的時間在期間內自行購買股份。查看Senti Biosciences的最新消息通常可以確定該公司是否最近批准了股票回購計劃。股票回購計劃通常作爲股價的支撐，爲需求提供後盾。
For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of Global Net Lease by the Jul. 11, 2024. Once done, you can expect to receive a nominal payout of $0.28 on Jul. 16, 2024.
例如，如果你想獲得14.97%的年化回報率，你需要在2024年7月11日之前購買一份Global Net Lease的股份。一旦完成，你可以期望在2024年7月16日獲得0.28美元的名義支付。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Senti Biosciences will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
股票回購計劃顯然是不同的，並且高度可變。公司可以批准股票回購計劃，並根據授權的時間在期間內自行購買股份。查看Senti Biosciences最新消息通常可以確定該公司是否最近批准了股票回購計劃。股票回購計劃通常作爲股價的支撐，提供需求支持。
According to data from Benzinga Pro, SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.
據Benzinga Pro的數據，SNTI的52周最高價爲1.09美元，52周最低價爲0.21美元。
譯文內容由第三人軟體翻譯。